Molecular regulation of tumour angiogenesis by nitric oxide

European Cytokine Network

Volumn 20, Issue 4, 2009, Pages 164-170

  Ziche, Marina ^a   Morbidelli, Lucia ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Angiogenesis; Endothelial cell; Metalloproteinases; Nitric oxide; Tumor

Indexed keywords

ANGIOPOIETIN; CALCIUM BINDING PROTEIN; CALMODULIN BINDING PROTEIN; CYCLIC GMP; CYCLOOXYGENASE 2; DNA; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ESTROGEN; FIBROBLAST GROWTH FACTOR 2; GUANYLATE CYCLASE; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; METALLOPROTEINASE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORADRENALIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; SPHINGOSINE 1 PHOSPHATE; TISSUE INHIBITOR OF METALLOPROTEINASE; VASCULOTROPIN;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; BLOOD VESSEL TONE; CARCINOGENESIS; CARDIOVASCULAR FUNCTION; CELL INTERACTION; CELL PROLIFERATION; CORNEA; DNA SYNTHESIS; ENZYME ACTIVITY; METABOLIC STRESS; MICROENVIRONMENT; MOLECULAR DYNAMICS; MONOCYTE; NONHUMAN; RABBIT; REGULATORY MECHANISM; REVIEW; SHEAR STRESS; SINGLE NUCLEOTIDE POLYMORPHISM; SMOOTH MUSCLE FIBER; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANIMALS; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ORYCTOLAGUS CUNICULUS;

EID: 72249104353     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2009.0169     Document Type: Review

References (76)

1. Bonavida B, Khineche S, Huerta-Yepez S, Garbán H. Therapeutic potential of nitric oxide in cancer. Drug Resistance Uptodates 2006; 9: 157.
2. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer 2006; 6: 521.
3. Coulter JA, McCarthy HO, Roedl W, Wagner E, Robson T, Hirst DG. Nitric oxide - a novel therapeutic for cancer. Nitric Oxide 2008; 19: 192.
4. Fitzpatrick B, Mehibel M, Cowen RL, Stratford IJ. iNOS as a therapeutic target for treatment of human tumors. Nitric Oxide 2008; 19: 217.
5. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumor progression. Lancet Oncol 2001; 3: 149.
6. Lechner M, Lirk P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Sem Cancer Biol 2005; 15: 277.
7. Lasagna N, Fantappiè O, Solazzo M, et al. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res 2006; 66: 2673.
8. Schmidt HH, Hofmann H, Schindler U, Shutenko ZS, Cunningham DD, Feelisch M. No. NO from NO synthase. Proc Natl Acad Sci USA 1996; 93: 14492.
9. Ignarro LJ. Biosynthesis and metabolism of endothelium-derived nitric oxide. Ann Rev Pharmacol Toxicol 1990; 30: 535.
10. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001; 357: 593.
11. Ying L, Hofseth LJ. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res 2007; 67: 1407.
12. Cannon III RO. Role of nitric oxide in cardiovascular disease: focus on the endothelium. Clin Chem 1998; 44: 1809.
13. Ziche M, Morbidelli L, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994; 94: 2036.
14. Ziche M, Morbidelli L, Choudhuri R, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99: 2625. (Pubitemid 27259809)
15. Parenti A, Morbidelli L, Ledda F, Granger HJ, Ziche M. The bradykinin/B1 receptor promotes angiogenesis by upregulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J 2001; 15: 1487.
16. Donnini S, Solito R, Giachetti A, Granger HJ, Ziche M, Morbidelli L. Fibroblast growth factor-2 mediates Angiotensin-converting enzyme inhibitor-induced angiogenesis in coronary endothelium. J Pharmacol Exp Ther 2006; 319: 515. (Pubitemid 44776354)
17. Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 1993; 265: H586. (Pubitemid 23273595)
18. Jenkins DC, Charles IG, Thomsen LL, Moss DW, et al. Roles of nitric oxide in tumour growth. Proc Natl Acad Sci USA 1995; 92: 4392.
19. Chin K, Kurashima Y, Ogura T, Tajiri H, Yoshida S, Esumi H. Induction of vascular endothelial growth factor by nitric oxide in human glioblastoma and hepatocellular carcinoma cells. Oncogene 1997; 15: 437. (Pubitemid 27370993)
20. Frank S, Stallmeyer B, Kampfer H, Schaffner C, Pfeilschifter J. Differential regulation of vascular endothelial growth factor and its receptor fms-like-tyrosine kinase is mediated by nitric oxide in rat renal mesangial cells. Biochem J 1999; 338: 367. (Pubitemid 129512260)
21. Jadeski LC, Hum KO, Chakraborty C, Lala PK. Nitric oxide promotes murine mammary tumour growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. Int J Cancer 2000; 86: 30. (Pubitemid 30133983)
22. Yang HT, Yan Z, Abraham JA, Terjung RL. VEGF(121)- and bFGF-induced increase in collateral blood flow requires normal nitric oxide production. Am J Physiol 2001; 280: H1097.
23. Andrade SP, Hart IR, Piper PJ. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br J Pharmacol 1992; 107: 1092.
24. Maeda H, Noguchi Y, Sato K, Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 1994; 85: 331. (Pubitemid 24129610)
25. Tozer GM, Prise VE, Chaplin DJ. Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine. Cancer Res 1977; 57: 948.
26. Malone JM, Saed GM, Diamond MP, Sokol RJ, Munkarah AR. The effects of the inhibition of inducible nitric oxide synthase on angiogenesis of epithelial ovarian cancer. Am J Obst Gynecol 2006; 194: 1110.
27. Thomsen LL, Lawton FG, Knowles RG, Beesley JE, Riveros-Moreno V, Moncada S. Nitric oxide synthase activity in human gynaecological cancer. Cancer Res 1994; 54: 1352. (Pubitemid 24108080)
28. Cobbs CS, Brenman JE, Aldape KD, Bredt DS, Israel MA. Expression of nitric oxide synthase in human central nervous system tumours. Cancer Res 1995; 55: 727.
29. Gallo O, Masini E, Morbidelli L, et al. Role of nitric oxide in angiogenesis and tumour progression in head and neck cancer. J Natl Cancer Inst 1998; 90: 587. (Pubitemid 28204802)
30. Kojima M, Morisaki T, Tsukahara Y, et al. Nitric oxide synthase expression and nitric oxide production in human colon carcinoma tissue. J Surg Oncol 1999; 70: 222. (Pubitemid 29187907)
31. Swana HS, Smith SD, Perrotta PL, Saito N, Wheeler MA, Weiss RM. Inducible nitric oxide synthase with transitional cell carcinoma of the bladder. J Urology 1999; 161: 630.
32. Marrogi AJ, Travis WD, Welsh JA, et al. Nitric oxide synthase, cyclooxygenase 2, and vascular endothelial growth factor in the angiogenesis of non-small cell lung carcinoma. Clin Cancer Res 2000; 6: 4739.
33. Vakkala M, Kahlos K, Lakari E, Paakko P, Kinnula V, Soini Y. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas. Clin Cancer Res 2000; 6: 2408. (Pubitemid 30399209)
34. Uotila P, Valve E, Martikainen P, Nevalainen M, Nurmi M, Harkonen P. Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer. Urology Res 2001; 29: 23.
35. Aaltoma SH, Lipponen PK, Kosma VM. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer. Anticancer Res 2001; 21: 3101.
36. Massi D, Franchi A, Sardi I, et al. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions. J Pathol 2001; 194: 194. (Pubitemid 32519969)
37. Ziche M, Morbidelli L, Masini E, Geppetti P, Granger HJ, Ledda F. Nitric oxide promotes DNA synthesis and cyclic GMP formation in endothelial cells from postcapillary venules. Biochem Biophys Res Commun 1993; 192: 1198. (Pubitemid 23218541)
38. Zaragoza C, Soria E, Lopez E, et al. Activation of the mitogen activated protein kinase extracellular signal-regulated kinase 1 and 2 by the nitric oxide-cGMP-cGMP-dependent protein kinase axis regulates the expression of matrix metalloproteinase 13 in vascular endothelial cells. Mol Pharmacol 2002; 62: 927.
39. Kawasaki K, Smith RS Jr, Hsieh CM, Sun J, Chao J, Liao JK. Activation of the phosphatidylinositol 3-kinase/protein kinase Akt pathway mediates nitric oxide-induced endothelial cell migration and angiogenesis. Mol Cell Biol 2003; 23: 5726. (Pubitemid 36951336)
40. Oliveira CJ, Schindler F, Ventura AM, et al. Nitric oxide and cGMP activate the Ras-MAP kinase pathway-stimulating protein tyrosine phosphorylation in rabbit aortic endothelial cells. Free Rad Biol Med 2003; 35: 381. (Pubitemid 37289168)
41. Duda DG, Fukumura D, Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Molecular Med 2004; 10: 143.
42. Morbidelli L, Chang CH, Douglas JG, Granger HJ, Ledda F, Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol 1996; 270: H411. (Pubitemid 126756100)
43. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131. (Pubitemid 28022851)
44. Ziche M, Parenti A, Ledda F, et al. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res 1997; 80: 845.
45. He H, Venema VJ, Gu X, Venema RC, Marrero MB, Caldwell RB. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through Flk-1/KDR activation of c-src. J Biol Chem 1999; 274: 25130. (Pubitemid 129529409)
46. Parenti A, Morbidelli L, Cui XL, et al. Nitric oxide is an upstream signal for vascular endothelial growth factor-induced extracellular signal-regulated kinases1/2 activation in postcapillary endothelium. J Biol Chem 1998; 273: 4220.
47. Radisavljevic Z, Avraham H, Avraham S. Vascular endothelial growth factor up-regulates ICAM-1 expression via phosphatidylinositol 3OH-kinase/AKT/nitric oxide pathway and modulates migration of brain microvascular endothelial cells. J Biol Chem 2000; 275: 20770.
48. Grasselli A, Nanni S, Colussi C, et al. Estrogen receptor-alpha and endothelial nitric oxide synthase nuclear complex regulates transcription of human telomerase. Circ Res 2008; 103: 34.
49. Igarashi J, Michel T. S1P and eNOS regulation. Biochim Biophys Acta 2008; 1781: 489.
50. Veikkola T, Karkkainer M, Claesson-Welsh L, Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60: 203. (Pubitemid 30070735)
51. Kroll J, Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 1998; 252: 743. (Pubitemid 28556847)
52. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 43: H1054. (Pubitemid 28158304)
53. Venema RC, Venema VJ, Ju H, et al. Novel complexes of guanylate cyclase with heat shock protein 90 and nitric oxide synthase. Am J Physiol 2003; 285: H669.
54. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. Eur Resp J 1994; 7: 2062.
55. Okamoto T, Akaike T, Nagano T, et al. Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide. Arch Biochem Biophys 1997; 342: 261.
56. Donnini S, Monti M, Roncone R, et al. Peroxynitrite inactivates human-tissue inhibitor of metalloproteinase-4. FEBS Lett 2008; 582: 1135.
57. Lizarbe TR, García-Rama C, Tarín C, et al. Nitric oxide elicits functional MMP-13 protein-tyrosine nitration during wound repair. FASEB J 2008; 22: 3207.
58. Namkoong S, Lee SJ, Kim CK, et al. Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells. Exp Mol Med 2005; 37: 588.
59. Kimura H, Weisz A, Kurashima Y, et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000; 95: 189.
60. Sandau KB, Zhou J, Kietzmann T, Brune B. Regulation of the hypoxia-inducible factor 1α by the inflammatory mediators nitric oxide and tumor necrosis factor-α in contrast to desferroxamine and phenylarsine oxide. J Biol Chem 2001; 276: 39805. (Pubitemid 37391388)
61. Kasuno K, Takabuchi S, Fukuda K, et al. Nitric oxide induces hypoxia inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem 2004; 279: 2550. (Pubitemid 38114240)
62. Metzen E, Zhou J, Jelkmann W, Fandrey J, Brune B. Nitric oxide impairs normoxic degradation of HIF-1α by inhibition of prolyl hydroxylases. Mol Biol Cell 2003; 14: 3470. (Pubitemid 37013142)
63. Quintero M, Brennan PA, Thomas GJ, Moncada S. Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1α in cancer: role of free radical formation. Cancer Res 2006; 66: 770. (Pubitemid 43165941)
64. Andrew PJ, Harant H, Lindley IJ. Nitric oxide regulates IL-8 expression in melanoma cells at the transcriptional level. Biochem Biophys Res Commun 1995; 214: 949.
65. Xiong Q, Shi Q, Le X, Wang B, Xie K. Regulation of interleukin-8 expression by nitric oxide in human pancreatic adenocarcinoma. J Interferon Cytokine Res 2001; 21: 529. (Pubitemid 32881459)
66. Conelly L, Jacobs AT, Placious-Callender M, Moncada S, Hobbs AJ. Macrophage endothelial nitric oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J Biol Chem 2003; 278: 26480.
67. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer. Mutation Res 2008; 659: 15.
68. Cianchi F, Cortesini C, Fantappie O, et al. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 2004; 10: 2694. (Pubitemid 38509144)
69. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio- resistance: Novel strategy for cancer therapy: Nitric oxide donor as a therapeutic enhancer. Nitric Oxide 2008; 19: 205.
70. Ng QS, Goh V, Milner J, et al. Effect of nitric oxide synthesis on tumor blood volume and vascular activity: a phase I study. Lancet Oncol 2007; 8: 111. (Pubitemid 46158370)
71. Choi JY, Lee KM, Noh DY, et al. Genetic polymorphisms of eNOS, hormone receptor status, and survival of breast cancer. Breast Cancer Res Treat 2006; 100: 213.
72. Lu J, Wei Q, Bondy ML, et al. Promoter polymorphism (-786t>C) in the endothelial nitric oxide synthase gene is associated with risk of sporadic breast cancer in non-Hispanic white women age younger than 55 years. Cancer 2006; 107: 2245. (Pubitemid 44665660)
73. Lee KM, Kang D, Park SK, et al. Nitric oxide synthase gene polymorphisms and prostate cancer risk. Carcinogenesis 2009; 30: 621.
74. Schelling ME, Meininger CJ, Hawker JR, Granger HJ. Venular endothelial cells from bovine heart. Am J Physiol 1988; 254: H1211.
75. Morbidelli L, Donnini S, Chillemi F, Giachetti A, Ziche M. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin Cancer Res 2003; 9: 5358. (Pubitemid 37413591)
76. Caenazzo C, Onisto M, Sartor L, et al. Augmented membrane type 1 matrix metalloproteinase (MT1-MMP):MMP-2 messenger RNA ratio in gastric carcinomas with poor prognosis. Clin Cancer Res 1988; 4: 2179.